Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01320423
Other study ID # 99073
Secondary ID
Status Active, not recruiting
Phase N/A
First received March 18, 2011
Last updated March 18, 2011
Start date August 2010
Est. completion date August 2011

Study information

Verified date March 2011
Source Taipei Medical University WanFang Hospital
Contact n/a
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Interventional

Clinical Trial Summary

To establish whether a policy of earlier surgical evacuation of the haematoma in selected patients with spontaneous lobar ICH will improve outcome compared to a policy of initial conservative treatment. The trial will also help to better define the indications for early surgery.

This will overcome two of the criticisms of STICH (timing was too late and sometimes location was too deep). The subgroup identified in STICH is clinically sensible and the hypothesis identified for STICH II is in line with current neurosurgical opinion.


Description:

STICH II is an international multicentre randomised parallel group trial comparing early craniotomy to evacuate the haematoma with initial conservative treatment, following spontaneous superficial intracerebral haemorrhage affecting the lobar region only. Only patients for whom the treating neurosurgeon is in equipoise about the benefits of early craniotomy compared to initial conservative treatment are eligible for the trial. Outcome is measured at six months via a postal questionnaire including the Glasgow Outcome scale, Modified Rankin Scale, EuroQol and Barthel. Six hundred patients will be recruited to the trial over thirty months. Follow-up will take six months with analysis and reporting taking one year.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 600
Est. completion date August 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Evidence of a spontaneous lobar ICH on CT scan (1 cm or less from the cortex surface of the brain)

- Patient within 48 hours of ictus

- Best MOTOR score on the GCS of 5 or 6 and best EYE score on the GCS of 2 or more.

- Volume of haematoma between 10 and 100ml [Calculated using (a x b x c)/2 method]

Exclusion Criteria:

- Clear evidence that the haemorrhage is due to an aneurysm or angiographically proven arteriovenous malformation.

- Intraventricular haemorrhage of any sort

- ICH secondary to tumour or trauma.

- Basal ganglia, thalamic, cerebellar or brainstem haemorrhage or extension of a lobar haemorrhage into any of these regions.

- Severe pre-existing physical or mental disability or severe co-morbidity which might interfere with assessment of outcome.

- If surgery cannot be performed within 12 hours.

- If the haematological effects of any previous anticoagulants are not completely reversed.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Surgical Trial
Surgical Trial in Lobar Intracerebral Haemorrhage

Locations

Country Name City State
Taiwan Taipei Medical University Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glasgow Outcome Scale/ Modified Rankin Scale Unfavourable outcome will be death or severe disability which will be defined using a prognosis based 8 point Glasgow Outcome Scale/ Modified Rankin Scale six months No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06429332 - International Care Bundle Evaluation in Cerebral Hemorrhage Research Phase 4
Completed NCT01563445 - Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage Phase 2
Not yet recruiting NCT06410274 - Ischaemic Lesions in Acute Intracerebral Haemorrhage
Completed NCT00127283 - Recombinant Factor VIIa in Acute Intracerebral Haemorrhage Phase 3
Completed NCT03737344 - BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage Phase 2
Completed NCT02162017 - Head Position in Stroke Trial (HeadPoST) N/A
Completed NCT03385928 - STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units Phase 2
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Active, not recruiting NCT01947361 - Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber) N/A
Active, not recruiting NCT01937065 - Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study N/A
Completed NCT00266006 - Factor VIIa in Acute Intracerebral Haemorrhage Phase 2
Recruiting NCT05369351 - Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage Phase 2
Recruiting NCT05681988 - Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH) N/A
Completed NCT02880878 - ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH) N/A
Completed NCT02176174 - Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study N/A
Completed NCT01702636 - STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial Phase 2
Completed NCT00426803 - Recombinant Factor VIIa in Acute Intracerebral Haemorrhage Phase 2
Completed NCT01566786 - Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage Phase 2
Recruiting NCT03044184 - Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial Phase 3